Increased CD47 expression in AML hematopoietic stem cells (HSCs) has been independently correlated with inferior outcomes, thus making the CD47/SIRPa axis an appealing therapeutic target [71]. This evidence concerns the gene CD47 and acute myeloid leukemia.